Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the completion of the sale, the chief financial officer now owns 23,000 shares of the company’s stock, valued at $490,590. This represents a 12.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, March 24th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.50, for a total value of $22,500.00.
• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total transaction of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $25,040.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $19.68 on Tuesday. The firm has a 50 day moving average price of $21.24 and a 200 day moving average price of $23.72. The stock has a market cap of $964.40 million, a P/E ratio of -10.36 and a beta of 1.04. Enliven Therapeutics, Inc. has a 52-week low of $15.96 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. Analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. HC Wainwright increased their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $38.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ELVN. Barclays PLC raised its position in Enliven Therapeutics by 295.8% during the third quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after acquiring an additional 42,012 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Enliven Therapeutics by 9.9% during the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock worth $19,164,000 after purchasing an additional 67,813 shares during the last quarter. Patient Square Capital LP bought a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at about $2,313,000. Charles Schwab Investment Management Inc. lifted its stake in Enliven Therapeutics by 10.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after purchasing an additional 24,043 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Enliven Therapeutics by 12.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock worth $668,000 after purchasing an additional 2,944 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.